Drugs in Dev.
Genetic Disease
Undisclosed
Spain 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Ysios Capital
Deal Size : $56.6 million
Deal Type : Series A Financing
Details : The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Ysios Capital
Deal Size : $56.6 million
Deal Type : Series A Financing
